Volume 16, Number 4—April 2010
Pandemic (H1N1) 2009 Risk for Nurses after Trivalent Vaccination
Highlight and copy the desired format.
|EID||Loeb MB, Earn DJ, Smieja M, Webby RJ. Pandemic (H1N1) 2009 Risk for Nurses after Trivalent Vaccination. Emerg Infect Dis. 2010;16(4):719-720. https://dx.doi.org/10.3201/eid1604.091588|
|AMA||Loeb MB, Earn DJ, Smieja M, et al. Pandemic (H1N1) 2009 Risk for Nurses after Trivalent Vaccination. Emerging Infectious Diseases. 2010;16(4):719-720. doi:10.3201/eid1604.091588.|
|APA||Loeb, M. B., Earn, D. J., Smieja, M., & Webby, R. J. (2010). Pandemic (H1N1) 2009 Risk for Nurses after Trivalent Vaccination. Emerging Infectious Diseases, 16(4), 719-720. https://dx.doi.org/10.3201/eid1604.091588.|
To the Editor: We report results of the effect of inactivated seasonal influenza vaccination on risk of pandemic (H1N1) 2009 in a cohort of nurses in Canada who participated in a recent randomized controlled trial that compared the effectiveness of surgical masks with that of N95 respirators in preventing influenza (1). From September 23, 2008, through December 8, 2008, a total of 446 nurses from 8 hospitals in the province of Ontario were enrolled. They were then randomly assigned an intervention; 225 were assigned to wear surgical masks, and 221 were assigned to wear the N95 respirator. The mean age of participants was 36.2 years; 94% were women. A total of 128 (30.3%) received the trivalent influenza vaccine. Vaccination status was similar between the groups: 68 (30.2%) persons in the surgical mask group and 62 (28.1%) persons in the N95 respirator group had received the 2008–2009 trivalent inactivated influenza vaccine. The nurses were monitored from January 12, 2009, through April 23, 2009.
Blood specimens for serologic analysis were obtained before enrollment and at the end of the follow-up period. End-of-study serum samples were collected from April 23 through May 15, 2009. Serologic infection was defined by a >4-fold increase in influenza-specific hemagglutinin inhibition assay titer between baseline and convalescent-phase serum samples by using turkey erythrocytes and A/TN/1560/2009(H1N1), a representative pandemic influenza virus.
Of the 422 nurses included in the analysis, 42 (10.0%) showed seroconversion to pandemic (H1N1) 2009. Of 128 nurses who received the trivalent influenza vaccine, 9 (7.0%) showed seroconversion vs. 33 (11.2%) of those that did not (relative risk 0.63, 95% confidence interval 0.31–1.27, p = 0.19).
Although the point estimate was protective, the confidence interval is wide and does not exclude an increase in risk. Our sample size limits inferences that can be drawn. Heterotypic antibodies may have contributed to the relatively high rate of seroconversion. A rise in antibody titer is considered by some as an outcome associated with bias, unlike virus identification. Nevertheless, these data suggest a possible positive effect of seasonal influenza vaccine reducing risk of infection with pandemic (H1N1) 2009.
This study was funded by the Public Health Agency of Canada.
- Loeb M, Dafoe N, Mahony J, John M, Sarabia A, Glavin V, JAMA. 2009;302:1865–71.Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Mark Loeb, McMaster University, 1200 Main St W, Hamilton, Ontario L8N 3Z5, Canada
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 28, 2010
- Page last updated: December 28, 2010
- Page last reviewed: December 28, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)